Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay

Breast Cancer Research and Treatment

Volumn 144, Issue 2, 2014, Pages 273-285

  Barros, Fabrício F T ^a   Abdel Fatah, Tarek M A ^a   Moseley, Paul ^a   Nolan, Christopher C ^a   Durham, Alice C ^a   Rakha, Emad A ^a   Chan, Stephen ^a   Ellis, Ian O ^a   Green, Andrew R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; HER2; Heterodimer; PLA; Trastuzumab

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GROWTH FACTOR RECEPTOR; HETERODIMER; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TRASTUZUMAB; TUMOR NECROSIS FACTOR; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ASSAY; BREAST CANCER; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CHROMOGENIC IN SITU PROXIMITY LIGATION ASSAY; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; GENE; GENE AMPLIFICATION; GENE EXPRESSION; HER2 GENE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SURVIVAL RATE; ADULT; AGED; BREAST NEOPLASMS; ENZYMOLOGY; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEIN MULTIMERIZATION; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTEIN MULTIMERIZATION; RECEPTOR, ERBB-2;

EID: 84896542635     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2871-4     Document Type: Conference Paper

References (44)

1. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, DunningMJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S; METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346-352
2. Tsuda H (2008) Individualization of breast cancer based on histopathological features and molecular alterations. Breast Cancer 15(2):121-132
3. Yu DH, Hung MC (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19(53):6115-6121
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2lneu oncogene. Science 235:177-183
5. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200:290-297 (Pubitemid 36827302)
6. Koninki K, Tanner M, Auvinen A, Isola J (2009) HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005. Breast Cancer Res 11(3):R37
7. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4(5):361-370 (Pubitemid 38579482)
8. Vandergeer P, Hunter T, Lindberg RA (1994) Receptor protein-tyrosine kinases and their signal-transduction pathways. Annu Rev Cell Biol 10:251-337 (Pubitemid 24372822)
9. Zwick E, Bange J, Ullrich A (2001) Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8(3):161-173 (Pubitemid 32947638)
10. Heldin CH (1996) Protein tyrosine kinase receptors. Cancer Surv 27:7-24 (Pubitemid 26363820)
11. Hudis CA (2007) Drug therapy: trastuzumab mechanism of action and use in clinical practice. N Engl J Med 357(1):39-51
12. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TPJ, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12(3):541-552 (Pubitemid 37222478)
13. Tzahar E, Waterman H, Chen XM, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y (1996) A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16(10):5276-5287 (Pubitemid 26315047)
14. Bartlett JMS, Ibrahim M, Jasani B, Morgan JM, Ellis I, Kay E, Connolly Y, Campbell F, O'Grady A, Barnett S, Miller K (2009) External quality assurance of HER2 FISH and ISH testing 3 years of the UK National External Quality Assurance Scheme. Am J Clin Pathol 131(1):106-111
15. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726 (Pubitemid 34111379)
16. Burris H, Yardley D, Jones S, Houston G, Broome C, Thompson D, Greco FA, White M, Hainsworth J (2004) Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as firstline treatment for patients with metastatic breast cancer. J Clin Oncol 22(9):1621-1629 (Pubitemid 41079800)
17. Slamon DJ, Jones BL, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming TEW, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N Engl J Med 344(11):783-792 (Pubitemid 32222155)
18. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20(21):4292-4302 (Pubitemid 35266289)
19. Barros FF, Powe DG, Ellis IO, Green AR (2010) Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology 56:560-572
20. Spears M, Taylor KJ, Munro AF, Cunningham CA, Mallon EA, Twelves CJ, Cameron DA, Thomas J, Bartlett JM (2011) In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat 132(2):463-470
21. Shinichi Tsutsui AK, Ohno Shinji, Murakami Shigeru, Kinoshita Junko, Hachitanda Yoichi (2002) Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 8:3454-3460
22. Sainsbury JRC, Malcolm AJ, Appleton DR, Farndon JR, Harris AL (1985) Presence of epidermal growth-factor receptor as an indicator of poor prognosis in patients with breast-cancer. J Clin Pathol 38(11):1225-1228 (Pubitemid 16215034)
23. Toi M, Tominaga T, Osaki A, Toge T (1994) Role of epidermal growth-factor receptor expression in primary breast-cancer: results of a biochemical-study and an immunocytochemical study. Breast Cancer Res Treat 29(1):51-58 (Pubitemid 24104837)
24. Suo Z, Risberg B, Klasson MG, Willman K, Tierens A, Skovlund E, Nesland JM (2002) EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196:17-25
25. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 11:340-350 (Pubitemid 40993329)
26. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Rwblamey J, Robertson FR, Nicholson R, Ellis I (2004) Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 91:1532-1542 (Pubitemid 39486359)
27. Margolis BL, Lax I, Kris R, Dombalagian M, Honegger AM, Howk R, Givol D, Ullrich A, Schlessinger J (1989) All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. J Biol Chem 264(18):10667-10671 (Pubitemid 19161640)
28. Zhang XW, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-1149 (Pubitemid 43866200)
29. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW (1992) Pathological prognostic factors in breast-cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20(6):479-489
30. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403-410
31. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22(3):207-219
32. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AHS, Robertson JF, Blamey RW, Macmillan D, Ellis IO (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42(18):3149-3156 (Pubitemid 44854512)
33. Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25-32 (Pubitemid 46120191)
34. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet J-S, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302-2310
35. Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bioinformatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252-7259 (Pubitemid 39487712)
36. de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96(10):1504-1513 (Pubitemid 46762956)
37. Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal-antibody reactive with a human nuclear antigen associated with cell-proliferation. Int J Cancer 31(1):13-20 (Pubitemid 13179545)
38. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16(7):1647-1655 (Pubitemid 27151960)
39. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8(1):11-31 (Pubitemid 32520251)
40. Zieba A, Wahlby C, Hjelm F, Jordan L, Berg J, Landegren U, Pardali K (2010) Bright-field microscopy visualization of proteins and protein complexes by in situ proximity ligation with peroxidase detection. Clin Chem 56(1):99-110
41. Soderberg O, Leuchowius K-J, Kamali-Moghaddam M, Jarvius M, Gustafsdottir S, Schallmeiner E, Gullberg M, Jarvius J, Landegren U (2007) Proximity ligation: a specific and versatile tool for the proteomic era. Genet Eng 28:85-93
42. Smirnova T, Zhou ZN, Flinn RJ, Wyckoff J, Boimel PJ, Pozzuto M, Coniglio SJ, Backer JM, Bresnick AR, Condeelis JS, Hynes NE, Segall JE (2012) Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene 31(6):706-715
43. Brennan PJ, Kumogai T, Berezov A, Murali R, Greene MI (2000) HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene 19(53):6093-6101 (Pubitemid 32059459)
44. Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T, Rijksen G (1998) Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 425(1):145-150 (Pubitemid 28149759)